Beijing's Immunotech Biopharm in-licensed China rights to a T-cell receptor (TCR) therapy for renal cell cancer from T-Cure Bio of Sherman Oaks, CA. T-Cure isolates high avidity TCRs to engineer a patient's T cells, allowing them to target and destroy solid tumors. T-Cure's 800TCR, which targets HERV-E, is currently being tested in a US Phase I trial in patients with metastatic clear cell renal cell carcinoma. Details of the agreement were not disclosed. More details.... Stock Symbol: (HK: 6978) Share this with colleagues: // //